Beginning in 2020, the COVID-19 pandemic caused by SARS-CoV-2 remains ongoing. However, in 2022 this virus has a different diffusion in the population compared to at the beginning of pandemic. Together with personal safety measures that aimed to reduce environmental transmission (e.g., wearing a face mask, reduced numbers of people in public areas, frequent cleaning of hands, and climatic variation and circulation of virus), the COVID-19 vaccination campaign gradually reduced the number of patients infected with severe COVID-19 (i.e., lung failure with increased morbidity, mortality and hospitalization rate). However, mortality is frequently associated with the presence of specific risk factors [1,2].
Yet, regarding the presence of viral variants of concern (VOCs), associated with immunization against the spike protein, the vaccination campaign actually reduced not only the severity of the disease and the clinical approach to infected patients but also clinical signs and symptoms of infection. In this Special Issue, we focus our attention on studies that describe specific and different clinical presentations of SARS-CoV-2 infection and also of post COVID-19.
Furthermore, the occurrence of severe COVID-19 is still possible in vulnerable categories of patients, such as non-responders to specific vaccines, immunocompromised patients and anti-vax people. In these cases, recent clinical improvements have been reported with use of specific antiviral drugs, such as remdesivir [3], and with new and improved ventilation support [3,4,5]. However, the most common severe complications of COVID-19 remain bacterial or fungal overinfection [6], pneumothorax and/or pneumomediastinum [7], or thrombotic complications (frequently pulmonary embolism) with or without associated molecular thrombophilia [8].
Neurological manifestations are frequent and could also appear with rare clinical signs and symptoms [9] in the subacute phase [10]. Neurological dysfunctions and cognitive impairment may be also responsible for sarcopenia and the slimming of infected patients [11].
Regarding atypical neurological symptoms and signs, cutaneous signs may appear as a rare manifestation of COVID-19 [12].
A comprehensive medical education is necessary for effective clinical practice, and day-by-day we are discovering more about the natural history of the new strain of coronavirus SARS-CoV-2 and the COVID-19 pandemic. Therefore, in this Special Issue, we present several atypical clinical aspects that may be vital for a clinical update of the natural history of this viral infection.
P.D.M. wrote the draft, G.F. checked manuscript, A.A. checked references. All authors have read and agreed to the published version of the manuscript.
Not applicable.
Not applicable.
The authors declare no conflict of interest.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
1. Rehman, S.; Rehman, N.; Mumtaz, A.; Jiang, J. Association of Mortality-Related Risk Factors in Patients with COVID-19: A Retrospective Cohort Study. Healthcare; 2021; 9, 1468. [DOI: https://dx.doi.org/10.3390/healthcare9111468] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34828513]
2. Miftode, E.; Miftode, L.; Coman, I.; Prepeliuc, C.; Obreja, M.; Stămăteanu, O.; Părângă, T.G.; Leca, D.; Pleşca, C.E. Diabetes Mellitus—A Risk Factor for Unfavourable Outcome in COVID-19 Patients—The Experience of an Infectious Diseases Regional Hospital. Healthcare; 2021; 9, 788. [DOI: https://dx.doi.org/10.3390/healthcare9070788] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34201473]
3. Simioli, F.; Nicoletta, C.; Valentino, M.R.; Martino, M.; Annunziata, A.; Carannante, N.; Di Micco, P.; Fiorentino, G. Remdesivir in Severe COVID-19 and Non-Invasive Ventilation: A Real-Life Experience. Healthcare; 2021; 9, 1108. [DOI: https://dx.doi.org/10.3390/healthcare9091108] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34574882]
4. Simioli, F.; Annunziata, A.; Polistina, G.E.; Coppola, A.; Di Spirito, V.; Fiorentino, G. The Role of High Flow Nasal Cannula in COVID-19 Associated Pneumomediastinum and Pneumothorax. Healthcare; 2021; 9, 620. [DOI: https://dx.doi.org/10.3390/healthcare9060620] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34067404]
5. Yang, C.-P.; Luk, H.-N.; Qu, J.Z.; Shikani, A. The Use of a Video-Assisted Intubating Stylet Technique in a Critically Ill and Contagious COVID-19 Patient. Healthcare; 2022; 10, 388. [DOI: https://dx.doi.org/10.3390/healthcare10020388] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/35207001]
6. Alhuofie, S.T.S. An Elderly COVID-19 Patient with Community-Acquired Legionella and Mycoplasma Coinfections: A Rare Case Report. Healthcare; 2021; 9, 1598. [DOI: https://dx.doi.org/10.3390/healthcare9111598] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34828643]
7. Szewczyk, A.K.; Skrobas, U.; Jamroz-Wiśniewska, A.; Mitosek-Szewczyk, K.; Rejdak, K. Facial Diplegia—Complication or Manifestation of SARS-CoV-2 Infection? A Case Report and Systemic Literature Review. Healthcare; 2021; 9, 1492. [DOI: https://dx.doi.org/10.3390/healthcare9111492] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34828542]
8. Moretta, P.; Ambrosino, P.; Lanzillo, A.; Marcuccio, L.; Fuschillo, S.; Papa, A.; Santangelo, G.; Trojano, L.; Maniscalco, M. Cognitive Impairment in Convalescent COVID-19 Patients Undergoing Multidisciplinary Rehabilitation: The Association with the Clinical and Functional Status. Healthcare; 2022; 10, 480. [DOI: https://dx.doi.org/10.3390/healthcare10030480] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/35326958]
9. Bologna, C.; Pone, E. Clinical Study on the Efficacy and Safety of Arginine Administered Orally in Association with Other Active Ingredients for the Prevention and Treatment of Sarcopenia in Patients with COVID-19-Related Pneumonia, Hospitalized in a Sub-Intensive Care Unit. Healthcare; 2022; 10, 162. [DOI: https://dx.doi.org/10.3390/healthcare10010162] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/35052325]
10. Laza, R.; Musta, V.F.; Nicolescu, N.D.; Marinescu, A.R.; Mocanu, A.; Vilceanu, L.; Paczeyka, R.; Cut, T.G.; Lazureanu, V.E. Cutaneous Manifestations in SARS-CoV-2 Infection—A Series of Cases from the Largest Infectious Diseases Hospital in Western Romania. Healthcare; 2021; 9, 800. [DOI: https://dx.doi.org/10.3390/healthcare9070800] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34202233]
11. Mormile, I.; Mormile, M.; Rea, G.; Petraroli, A.; Barbieri, V.; de Paulis, A.; Rossi, F.W. Spontaneous Pneumo-Mediastinum in a Post-COVID-19 Patient with Systemic Sclerosis. Healthcare; 2022; 10, 529. [DOI: https://dx.doi.org/10.3390/healthcare10030529]
12. Badulescu, O.V.; Sirbu, P.D.; Filip, N.; Bordeianu, G.; Cojocaru, E.; Budacu, C.C.; Badescu, M.C.; Bararu-Bojan, I.; Veliceasa, B.; Ciocoiu, M. Hereditary Thrombophilia in the Era of COVID-19. Healthcare; 2022; 10, 993. [DOI: https://dx.doi.org/10.3390/healthcare10060993] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/35742044]
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.